STERIS FY26 revenue $5.9B (+9%), adj EPS $10.17; FY27 guidance adj EPS $11.10-$11.30

STERIS plc

• Full year revenue from continuing ops $5.9B (+9%), constant currency organic +7%; adjusted EPS $10.17 vs $9.22.
• Q4 revenue $1.6B (+7%), adjusted EPS $2.83 vs $2.74; Healthcare rev $1.14B (+7%), AST $289.2M (+6%), Life Sci $162.9M (+9%).
• FY26 operating cash flow $1.34B, free cash flow $982.9M (up from $787.2M).
• FY27 guidance: revenue +7-8%, organic +6-7%, adj EPS $11.10-$11.30 (9-11% growth), capex ~$375M, FCF ~$850M.
• Board authorized new $1B share repurchase program; $60M strategic investment for new sterility plant in Mentor, Ohio (operational late CY2027).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.